Information

Search millions of cases and get court filings, fast docket alerts, and case analytics.

Request a Demo or create your account.

Lawyer? Your firm may have a group account, ask us and we'll let you know.

Click below for detailed party information:

Patent Owner

Sanofi-Aventis Deutschland GmbH

Petitioners

Mylan Pharmaceuticals Inc Pfizer Inc.,1 Pfizer

alt+h	Toggle this page.
alt+u	Toggle Upcoming Events view.
alt+e	Export the docket to Excel.
Filtering / Searching the Docket
ctrl+f	Filter the docket.
ctrl+shift+f	Search docket and documents.
alt+s	Toggle between "Show Only" filtering modes.
alt+d, ctrl+f	System ctrl+f
escape	Clear while in docket filter.
Interactive Timeline
alt+t	Show / re-center case timeline.
alt+↑	Zoom in
alt+↓	Zoom out
alt+←	Pan left
alt+→	Pan right

Mylan Pharmaceuticals Inc v. Sanofi-Aventis Deutschland GmbH

IPR2018-01680 | Patent Trial and Appeal Board

Interested in this case?

Request a Demo Track this case, and find millions of cases like it, let us show you how.

Filed Sept. 10, 2018

Terminated May 29, 2020

Judges Bart Gerstenblith, Hyun Jung, James Tartal, and James Mayberry

Case Type Inter Partes Review

Status Final Written Decision

Challenged Patent 15/156,616

Patent No. 9,526,844 assignments

Tech Center 3700

Art Unit 3763

Last Updated: 5 months ago

Filing Date	#	Filing and Exhibits
Entries matching. Show All.
8/10/2022	08-10-2022-Board	Board Other: other court decision 112: Other: other court decision Board Other: Fed Circuit mandate 113: Other: fed circuit mandate Board Trial Certificate Checklist 114: Trial Certificate Checklist
7/23/2020	07-23-2020-Patent_Owner	Event: Notice of Appeal Patent Owner Notice of Appeal 111: Patent Owner Sanofi-Aventis Deutschland GmbH¿¿¿s Notice of Appeal Under 37 C.F.R. 90.2(a)
5/29/2020	05-29-2020-Board	Board Termination Decision Document 110: JUDGMENT Final Written Decision Determining All Challenged Claims Unpatentable Denying Patent Owner’s Motion to Amend Denying Petitioner’s Motion to Exclude 35 U.S.C. § 318(a)
4/8/2020	04-08-2020-Patent_Owner	Patent Owner Notice 109: Patent Owner¿¿¿s Updated Mandatory Notices Pursuant to 37 C.F.R. ¿¿ 42.8(b)(3)
4/7/2020	04-07-2020-Petitioner	Petitioner Notice 108: Petitioners' Mandatory Change-of-Information Notices
4/1/2020	04-01-2020-Board	Board Order 107: ORDER Granting Patent Owner's Motion for Withdrawal of Counsel
3/25/2020	03-25-2020-Board	Board Order 106: ORDER Adjusting One-Year Pendency Due to Joinder 35 U.S.C. ¿¿ 316(a)(11); 37 C.F.R ¿¿ 42.100(c)
3/13/2020	03-13-2020-Petitioner	Petitioner Exhibit List 105: Petitioners' Updated Exhibit List Petitioner Exhibit 1118: Sanofi-Aventis U.S. LLC v. Mylan GmbH, Case 2:17-cv-09105 (SRC), slip op. (D.N.J. entered Mar. 9, 2020) (collateral opinion on infringement and validity)
2/25/2020	02-25-2020-Board	Board Hearing Transcript 103: EXPUNGED Board Hearing Transcript 104: Hearing Transcript
2/24/2020	02-24-2020-Patent_Owner	Patent Owner Motion 102: Patent Owner¿¿¿s Motion for Withdrawal of Counsel
2/3/2020	02-03-2020-Patent_Owner	Patent Owner Other (Not for motions) 101: Patent Owner's Demonstratives
2/3/2020	02-03-2020-Petitioner	Petitioner Other (Not for motions) 100: Petitioners' Demonstratives
1/31/2020	01-31-2020-Patent_Owner	Patent Owner Objection 99: Patent Owner's Objections to Petitioners' Demonstratives
1/27/2020	01-27-2020-Petitioner	Petitioner Reply 97: Petitioners' Surreply to the Revised Motion to Amend Petitioner Exhibit List 98: Petitioners' Updated Exhibit List Petitioner Exhibit 1117: Deposition of Alexander Slocum taken 01-10-20
1/23/2020	01-23-2020-Petitioner	Petitioner Reply 96: Petitioner's Reply In Support of Motion to Exclude
1/17/2020	01-17-2020-Patent_Owner	Patent Owner Opposition 95: Patent Owner's Opposition to Petitioners' Motion to Exclude
1/15/2020	01-15-2020-Board	Board Order 93: ORDER Conduct of the Proceeding
1/15/2020	01-15-2020-Petitioner	Petitioner Exhibit List 94: Petitioners' Updated Exhibit List Petitioner Exhibit 1116: Transcript of PTAB Telephone Conference January 13, 2020 Petitioner Exhibit 1116: Transcript of PTAB Telephone Conference January 13, 2020
1/10/2020	01-10-2020-Petitioner	Petitioner Objection 91: Petitioners' Objections to Evidence Sanofi Reply - Revised Motion to Amend Petitioner Motion 92: Petitioners' Motion to Exclude
1/7/2020	01-07-2020-Board	Board Order 89: Oral Hearing 37 C.F.R. Section 42.70
1/7/2020	01-07-2020-Patent_Owner	Patent Owner Reply 90: Patent Owner's Reply to Petitioner's Opposition to Patent Owner's Revised Motion to Amend Patent Owner Exhibit 2329: Leinsing Deposition Exhibit 2329: Annotations of M¿¿ller-1 Patent Owner Exhibit 2330: Leinsing Deposition Exhibit 2330: Annotations of M¿¿ller-2 Patent Owner Exhibit 2331: Deposition of Karl R. Leinsing, dated December 20, 2019 for IPR2018-01679, -01680, -01682 Patent Owner Exhibit 2332: Declaration of Alexander Slocum, Ph.D. in Support of Sanofi's Reply to Mylan's Opposition to Sanofi's Revised Motion to Amend Patent Owner Exhibit 2333: Animation of Dr. Slocum¿¿¿s "Stinger" Model Patent Owner Exhibit 2334: Animation of Dr. Slocum¿¿¿s "Stinger" Model plus Externally Threaded Nut
1/6/2020	01-06-2020-Petitioner	Petitioner Notice of Deposition 88: Notice of Deposition of Alexander Slocum, Ph.D.
12/27/2019	12-27-2019-Patent_Owner	Patent Owner Response 86: Patent Owner's Responses to Petitioners' Observations
12/27/2019	12-27-2019-Petitioner	Petitioner Response 87: Petitioners¿¿¿ Response to Patent Owner¿¿¿s Observations on Testimony of Mr. Karl Leinsing
12/20/2019	12-20-2019-Patent_Owner	Patent Owner Other (Not for motions) 84: Patent Owner's Observations on the Cross-Examination of Mr. Karl Leinsing Patent Owner Exhibit 2227: Transcript of the Cross-Examination of Karl Leinsing
12/20/2019	12-20-2019-Petitioner	Petitioner Other (Not for motions) 85: Petitioner's Observations Regarding the Testimony of Alexander Slocum, Ph.D.
12/19/2019	12-19-2019-Patent_Owner	Patent Owner Oral Hearing Request 82: Patent Owner's Request for Oral Argument
12/19/2019	12-19-2019-Petitioner	Petitioner Oral Hearing Request 83: Petitioner's Request for Oral Argument
12/17/2019	12-17-2019-Petitioner	Event: Petition Petitioner Petition 80: Petitioner's Opposition To Patent Owner's Revised Motion to Amend Petitioner Exhibit List 81: Petitioner's Updated Exhibit List Petitioner Exhibit 1109: Deposition of Alexander Slocum (Dec. 10, 2019) Petitioner Exhibit 1110: Transcript of Telephone Conference on Dec. 11, 2019 Petitioner Exhibit 1111: Transcript of Telephone Conference on Dec. 13, 2019 Petitioner Exhibit 1112: US 2004/026728 A1 ¿¿¿ Veasey, ¿¿¿Pen Type Injector¿¿¿ (pub¿¿¿d. Dec. 30, 2004) Petitioner Exhibit 1113: Declaration of Karl R. Leinsing, MSME, PE, In Support of Petitioner¿¿¿s Oppositions to Sanofi¿¿¿s Revised Motion to Amend Petitioner Exhibit 1114: Transcript, Slocum direct testimony in Sanofi-Aventis U.S. LLC v. Mylan GmbH, Case 2:17-cv-09105-SRC-CLW (D.N.J., Dec. 4, 2019) Petitioner Exhibit 1115: Transcript, Slocum direct testimony in Sanofi-Aventis U.S. LLC v. Mylan GmbH, Case 2:17-cv-09105-SRC-CLW (D.N.J., Dec. 5, 2019)
12/17/2019	12-17-2019-Board	Board Order Conduct of Proceeding 79: Order Conduct of the Proceeding
12/16/2019	12-16-2019-Board	Board Order Conduct of Proceeding 78: Order Conduct of the Proceeding
11/26/2019	11-26-2019-Petitioner	Petitioner Notice of Deposition 77: Notice of Depositions of Alexander Slocum, Ph.D.
11/25/2019	11-25-2019-Patent_Owner	Patent Owner Notice 76: Joint Stipulation to Modify Due Dates in Revised Scheduling Order
11/22/2019	11-22-2019-Petitioner	Petitioner Exhibit List 75: Petitioner's Updated Exhibit List Petitioner Exhibit 1108: Transcript of Telephone Conference on November 18, 2019
11/21/2019	11-21-2019-Board	Board Order Conduct of Proceeding 74: Order Conduct of the Proceeding Board Exhibit 3002: Email
11/19/2019	11-19-2019-Patent_Owner	Patent Owner Motion 73: Patent Owner's Corrected Revised Contingent Motion to Amend Patent Owner Exhibit 2325: Declaration of Alexander Slocum, Ph.D. in Support of Sanofi¿¿¿s Revised Motions to Amend Patent Owner Exhibit 2326: Table of Equivalent Disclosure in U.S. Applications 13/909,681 (486 Patent) and 15/156,616 (844 Patent) and Related Applications for Revised Motions to Amend Patent Owner Exhibit 2327: Supplemental Disclosure Pursuant to 37 C.F.R. ¿¿ 42.11 Patent Owner Exhibit 2328: Sanofi3-90098102
11/18/2019	11-18-2019-Petitioner	Petitioner Notice 72: Petitioner's Mandatory Change-of-Information Notices
11/15/2019	11-15-2019-Board	Board Order Conduct of Proceeding 71: ORDER - Conduct of the Proceeding 37 C.F.R. 42.5
11/8/2019	11-08-2019-Board	Board Order 69: EXPUNGED Board Order 70: Revised Scheduling Order
11/6/2019	11-06-2019-Petitioner	Petitioner Objection 68: IPR2018-1680 Objections - 2019-11-06
10/30/2019	10-30-2019-Patent_Owner	Patent Owner Motion 66: Patent Owner's Revised Contingent Motion to Amend Patent Owner Reply 67: Patent Owner's Sur-Reply Patent Owner Exhibit 2223: SoloStar Wins Good Design Award Patent Owner Exhibit 2224: Expert Opinion on Drug Delivery Patent Owner Exhibit 2225: Excerpt from Merck Trial Transcript Patent Owner Exhibit 2314: Declaration of John Moffat Patent Owner Exhibit 2316: EXPUNGED Patent Owner Exhibit 2316: 2019-10-10 Leinsing Transcript Patent Owner Exhibit 2317: EXPUNGED Patent Owner Exhibit 2317: 2019-10-15 Biggs Transcript Patent Owner Exhibit 2318: EXPUNGED Patent Owner Exhibit 2318: 2019-10-9 McDuff Transcript Patent Owner Exhibit 2319: EXPUNGED Patent Owner Exhibit 2319: EXPUNGED Patent Owner Exhibit 2320: DCA0000436-DCA0000440 Patent Owner Exhibit 2321: DCA0000559-DCA0000564 Patent Owner Exhibit 2322: Novo Nordisk A/S Annual Financial Report 2003 Patent Owner Exhibit 2323: Deposition of David Plumptre Taken 04-26-2019 Patent Owner Exhibit 2324: Deposition of Andreas Bode Taken 05-03-2019
10/16/2019	10-16-2019-Board	Board Notice 65: Preliminary Guidance - Patent Owner's Motion to Amend
10/9/2019	10-09-2019-Petitioner	Petitioner Exhibit List 64: Petitioner's Updated Exhibit List
10/7/2019	10-07-2019-Patent_Owner	Patent Owner Notice of Deposition 61: Patent Owner's Notice of Deposition of Karl R. Leinsing Patent Owner Notice of Deposition 62: Patent Owner's Notice of Deposition of William Curtis Biggs Patent Owner Notice of Deposition 63: Patent Owner's Notice of Deposition of DeForest McDuff
10/2/2019	10-02-2019-Patent_Owner	Patent Owner Power of Attorney 59: Power of Attorney for Patent Owner Sanofi-Aventis Deutschland GmbH Patent Owner Notice 60: Patent Owner's Updated Mandatory Notices
9/27/2019	09-27-2019-Petitioner	Petitioner Notice 58: Petitioner's Mandatory Change-of-Information Notices
9/25/2019	09-25-2019-Patent_Owner	Patent Owner Objection 57: Patent Owner's Objections to Documents Served By Petitioner
9/18/2019	09-18-2019-Petitioner	Petitioner Reply 52: Petitioner's Reply to Patent Owner Response Petitioner Exhibit List 53: Petitioner's Updated Exhibit List Petitioner Reply 54: Petitioner's Reply to Patent Owner Response Petitioner Exhibit List 55: Petitioner's Updated Exhibit List Petitioner Opposition 56: Petitioner's Opposition to Patent Owner's Contingent Motion to Amend Petitioner Exhibit 1044: Nat¿¿¿l. Diabetes Statistic Report 2017, ¿¿¿Estimates of Diabetes and Its Burden in the United States, CDC, p.1-20 Petitioner Exhibit 1045: Teresa L. Pearson, ¿¿¿Practical Aspects of Insulin Pen Devices¿¿¿, Journal of Diabetes Science and Technology, Vol. 4, Issue 3, May 2010, p.522-531 Petitioner Exhibit 1046: Nancy J.V. Bohannon, ¿¿¿Insulin Delivery Using Pen Devices¿¿¿, Postgraduate Medicine, Vol. 106, No.5, Oct. 15, 1999, p. 57-68, ISSN: 0032-5481 (Print) 1941-9260 ¿¿¿ (Online) Journal homepage: https://www.tandfonline.com/loi/ipgm20 Petitioner Exhibit 1047: Marilyn R. Graff, RN, CDE et al., ¿¿¿Assessment by Patients with Diabetes Mellitus of Two Insulin Pen Delivery Systems Versus a Vial and Syringe¿¿¿, Clinical Therapeutics, Vol. 20, No. 3, 1998, p.486-196 Petitioner Exhibit 1048: Expert Declaration of William Curtis Biggs, M.D., FACE, ECNU in Support of Mylan-Pfizer Reply Petitioner Exhibit 1048: CORRECTED - Expert Declaration of William Curtis Biggs, M.D., FACE, ECNU in Support of Mylan-Pfizer Reply Petitioner Exhibit 1049: Curriculum Vitae of William Curtis Biggs, M.D., FACE, ECNU Petitioner Exhibit 1050: Slocum Deposition Exhibit 1050: Annotations of EX2107 (Declaration of Alexander Slocum Ph.D.) Petitioner Exhibit 1051: Slocum Deposition Exhibit 1051: Hand drawing of modified drive mechanism Petitioner Exhibit 1052: Slocum Deposition Exhibit 1052: Annotations of excerpted figures from EX2157 Petitioner Exhibit 1053: Deposition of Alexander H. Slocum, Ph.D., August 27, 2019 Petitioner Exhibit 1054: Deposition of Alexander H. Slocum, Ph.D., Vol II, August 28, 2019 Petitioner Exhibit 1055: Deposition of Henry Grabowski, Ph.D., Sep. 5, 2019 Petitioner Exhibit 1056: Deposition of Robin Goland, Sep. 10, 2019 Petitioner Exhibit 1057: Benita Lee, MPH, ¿¿¿How Much Does Insulin Cost? Here¿¿¿s How 23 Brands Compare¿¿¿, Good RX, Aug. 23, 2019, pp. 1-11, https:www.goodrx.com/glo/how-much-does-insuling-cost,compare-brands/ Petitioner Exhibit 1058: Certified English Translation of DE Patent 102 37 258A1, Dr. Roney Graf (Issued Mar. 182004) Petitioner Exhibit 1059: M. Eledrisi, et al., ¿¿¿Twice-Daily Insulin Glargine for Patients with Uncontrolled Type 2 Diabetes Mellitus, Journal of Clinical & Translational Endocrinology 15 (2019), p. 35-36 Petitioner Exhibit 1060: Declaration and c.v. of DeForrest McDuff, Ph.D. Petitioner Exhibit 1061: 2011 Orange Book (Excerpts) Petitioner Exhibit 1062: 2019 Orange Book (Excerpt ¿¿¿ ADA 132 of 263) Petitioner Exhibit 1063: 2011-02-09 - Sanofi SA Earnings Conference Call Petitioner Exhibit 1064: 2012-02-08 ¿¿¿ Sanofi SA Earnings Conference Call Petitioner Exhibit 1065: 2013-02-26 ¿¿¿ Sanofi SA at Citi Global HealthCare Conference Petitioner Exhibit 1066: 2014-02-06 ¿¿¿ Sanofi SA Earnings Conference Call Petitioner Exhibit 1067: Asamoah et al., ¿¿¿Insulin Pen ¿¿¿ The ¿¿¿iPod¿¿¿ for Insulin Delivery (Why Pen Wins Over Syringe)¿¿¿, J. of Diabetes Sci. and Technology, Vol. 2, Issue 2, March 2008, p.292-296 Petitioner Exhibit 1068: Aventis 2002 20-F Form Petitioner Exhibit 1069: Aventis 2003 20-F Form Petitioner Exhibit 1070: Sanofi-Aventis 2006 20 F Form Petitioner Exhibit 1071: Correa, Carlos, ¿¿¿Ownership of Knowledge ¿¿¿ the Role of Patents in Pharmaceutical R&D¿¿¿, Round Table, Bulletin of World Health Org., 2004; 82; p.1-7 Petitioner Exhibit 1072: Carter, Alan W., ¿¿¿Analysis of the Injection Force of Solostar¿¿ Compared with Other Disposable Insulin Pen Devices At Constant Volume Flow Rates¿¿¿, J. of Diabetes Sci. and Tech., Vol. 5, Issue 1, Jan. 2011, p. 156-157 Petitioner Exhibit 1073: ¿¿¿About Diabetes¿¿¿, CDC Basics, p.1-2, https://www.cdc.gov/diabetes/bascis/diabetes Petitioner Exhibit 1074: David, J. et al. ¿¿¿Commercial Success: Economic Principles Applied to Patent Litigation¿¿¿, NERA Economic Consulting (copyrighted material), p. 159-160 Petitioner Exhibit 1075: ¿¿¿Top Ten Tips on Writing Effectiveness Case Studies¿¿¿, By Design Business Association, May 23, 2016, p.1-5, https://www.dba.org.uk/review-top-ten-tips-on-writing-effectiveness-case-studies/ Petitioner Exhibit 1076: DiMasi, J., et al. ¿¿¿Innovation in the Pharmaceutical Industry: New Estimates of R&D Costs¿¿¿, J. of Health Economics47 (2016), p. 20-33 Petitioner Exhibit 1076: Declaration of Karl Leinsing ISO Petitioner's Opposition to Sanofi's Motion to Amend Petitioner Exhibit 1077: Grabowski, H., et al. ¿¿¿Returns on Research and Development for 1990s New Drug Introductions¿¿¿, Pharmacoeconomics 2002; 20 Suppl. 3: p. 11-29 Petitioner Exhibit 1078: Pietrangelo, Ann ¿¿¿Levemir vs. Lantus: Similarities and Differences¿¿¿, Healthline, Oct. 19, 2016, p.1-14, https://www.healthline.com/health/deiabetes/levemir-lantus Petitioner Exhibit 1079: U.S. Patent 6,100,376, ¿¿¿A21, B30, Modified Insulin Derivatives having An Altered Action Profile¿¿¿, M. D¿¿rschug (issued Aug. 8, 2000) Petitioner Exhibit 1080: Lewcock, Anna, ¿¿¿Sanofi¿¿¿s SoloStar Hits US Market Despite Patent Suit¿¿¿, in-Pharma Technologist.com, Jul. 20, 2007, https://www.in-pharmatechnologist.com/Article/2007/07/31/Sanofi-s-SoloStar-hits-US-market-despite-patent-suit Petitioner Exhibit 1081: Lantus, ¿¿¿Get to Know the Lantus¿¿ SoloStar¿¿ Insulin Pen, p. 1-7, https://www.lantus.com/get-to-know-the-lantus-solostar-pen Petitioner Exhibit 1082: Lantus SoloStar Brochure: ¿¿¿High Blood Sugar, You¿¿¿re Going Down¿¿¿ (2012) Petitioner Exhibit 1083: Lantus SoloStar Brochure: ¿¿¿Your Guide to the Lantus SoloStar Insulin Pen¿¿¿ (2010) Petitioner Exhibit 1084: McDuff, et al., ¿¿¿Thinking Economically About Commercial Success¿¿¿, Landslide, March/April 2017, p. 37-40 Petitioner Exhibit 1085: Nonaka, H., ¿¿¿FTO (Freedom to Operate) in the Pharmaceutical Industry¿¿¿, JSTOR, Pub. by Nomos Verlagsgesellschaft mbH (2018), p. 9-59 Petitioner Exhibit 1086: Senate Comm. On Finance Questions for the Record, ¿¿¿Drug Pricing in America¿¿¿: A Prescription for Change Part II, Questions for Olivier Brandicourt, CEO Sanofi, Feb. 26, 2019, p. 1-460 Petitioner Exhibit 1087: S.G. Cowen, ¿¿¿Perspectives¿¿¿, Pharmaceutical Therapeutic Categories Outlook, Oct. 2001, p.134-148 Petitioner Exhibit 1088: Cowen and Co., ¿¿¿Diabetes: Many New Drugs, But Insulin Still Dominant¿¿¿, Therapeutic Categories Outlook, Feb. 2015, p.477-491 Petitioner Exhibit 1089: UBS Large Cap Pharmaceuticals Handbook, ¿¿¿U.S. Pharmaceuticals¿¿¿, Apr. 6, 2018, p.45-53 Petitioner Exhibit 1090: Campbell, K., ¿¿¿Insulin Costs Are Skyrocketing. This is Why¿¿¿, U.S. New and World Report, Jun. 29, 2018, p.1-7 Petitioner Exhibit 1091: U.S. Patent 5,656,722, ¿¿¿A21, B30, Modified Insulin Derivatives having An Altered Action Profile¿¿¿, M. D¿¿rschug (issued Aug. 12, 1997) Petitioner Exhibit 1092: U.S. Patent 7,476,652, ¿¿¿Acidic Insulin Preparations Having Improved Stability¿¿¿, Brunner-Schwarz (issued Jan. 13, 2009) Petitioner Exhibit 1093: U.S. Patent 7,713,930, ¿¿¿Acidic Insulin Preparations Having Improved Stability¿¿¿, Brunner-Schwarz (issued May 11, 2010) Petitioner Exhibit 1094: WebMD, ¿¿¿Types of Insulin for Diabetes Treatment¿¿¿, p.1-7 https://www.webmd.com/diabetes/diabetes-types-insulin#1 Petitioner Exhibit 1095: Declaration of Karl Leinsing in Support of Support of Mylan-Pfizer Reply Petitioner Exhibit 1096: CORRECTED - Declaration of Karl Leinsing ISO Petitioner's Opposition to Sanofi's Motion to Amend Petitioner Exhibit 1097: WO 02/092153, Atterbury et al., ¿¿¿Medication Injector Apparatus with Drive Assembly that Facilitates Reset¿¿¿ (Pub¿¿¿d. Nov. 21, 2002) Petitioner Exhibit 1098: U.S. Patent 5,725,508 ¿¿¿Quick Connect Medication Delivery Pen¿¿¿, Chanoch, et al. (issued Mar. 10, 1998) Petitioner Exhibit 1099: EP 0 937 471, Walters et al., ¿¿¿Medication Delivery Pen¿¿¿ (Pub¿¿¿d. Aug. 25, 1999) Petitioner Exhibit 1100: GB 2 064 012, Lorscheidt, ¿¿¿Dose Dispenser for Pastes and Liquids¿¿¿ (Pub¿¿¿d. Jun 10. 1981) Petitioner Exhibit 1101: EP 0 667 469, Akram, ¿¿¿Ratchet mechanism Exploiting Both Strakes of the Ratchet Motion¿¿¿ (Pub¿¿¿d. Aug. 16, 1995) Petitioner Exhibit 1102: GB 2 384 431, Stamp, ¿¿¿Needleless Injection having an Audible Does Indicator¿¿¿ (Pub¿¿¿d. Jul. 30, 2003) Petitioner Exhibit 1103: U.S. Patent 5,000,650, ¿¿¿Split Nut¿¿¿, Haas, Jr. (issued Mar. 19, 1991) Petitioner Exhibit 1104: U.S. Patent 4,083,288, ¿¿¿Split Nuts¿¿¿, Williams (issued Apr. 11, 1978) Petitioner Exhibit 1105: U.S. Patent 6,277,099, ¿¿¿Medication Delivery Pen¿¿¿, Strowe, et al. (issued Aug. 21, 2001)
9/18/2019	09-18-2019-Patent_Owner	Patent Owner Exhibit List 51: Patent Owner's Updated Exhibit List Patent Owner Exhibit 2315: Transcript of 09-09-2019 Teleconference between Board and Parties
9/3/2019	09-03-2019-Board	Board Order 50: Order - Granting Patent Owner's Motions for Pro Hac Vice Admission of Anna E. Dwyer - 37 CFR 42.10
8/27/2019	08-27-2019-Petitioner	Petitioner Notice of Deposition 49: Notice of Deposition for Robin S. Goland, M.D.
8/22/2019	08-22-2019-Petitioner	Petitioner Notice of Deposition 48: Notice of Deposition for Henry Grabowski
8/19/2019	08-19-2019-Board	Board Order 47: DECISION Instituting Inter Partes Review and Granting Motion for Joinder 35 U.S.C. 314, 315(c) (IPR2019-01022)
8/16/2019	08-16-2019-Patent_Owner	Patent Owner Motion 46: Motion for Pro Hac Vice Admission Under 37 C.F.R. 42.10 Patent Owner Exhibit 2221: Declaration of Anna E. Dwyer in Support of Motion for Pro Hac Vice Admission Under 37 C.F.R. 42.10 Patent Owner Exhibit 2222: Biography of Anna E. Dwyer
8/14/2019	08-14-2019-Patent_Owner	Patent Owner Notice 45: Notice of Joint Stipulation to Modify Due dates 2, 3, 5, and 6
8/13/2019	08-13-2019-Petitioner	Petitioner Notice of Deposition 44: Notice of Deposition of Alexander Slocum, Ph.D.
8/8/2019	08-08-2019-Board	Board Order Conduct of Proceeding 43: Order - 37 C.F.R. 42.5
8/5/2019	08-05-2019-Board	Board Order 42: ORDER - Granting Patent Owner¿¿¿s Motions for Pro Hac Vice Admission of Robert Vlasis 37 C.F.R. ¿¿ 42.10
7/29/2019	07-29-2019-Petitioner	Petitioner Exhibit List 41: Petitioner's Updated Exhibit List Petitioner Exhibit 1043: Transcript of Telephone Conference on July 25, 2019
7/19/2019	07-19-2019-Patent_Owner	Patent Owner Motion 40: Motion for Pro Hac Vice Admission Under 37 C.F.R. 42.10 Patent Owner Exhibit 2200: Biography of Robert T. Vlasis Patent Owner Exhibit 2219: Declaration of Robert T. Vlasis
7/17/2019	07-17-2019-Petitioner	Petitioner Notice 39: Petitioner's Mandatory Change-of-Information Notices
7/9/2019	07-09-2019-Patent_Owner	Patent Owner Exhibit 2109: Declaration of Henry R. Grabowski, Ph.D. (CORRECTED)
7/2/2019	07-02-2019-Petitioner	Petitioner Objection 38: Mylan Pharmaceuticals Inc. Objections To Sanofi's Motion To Amend Evidence
7/1/2019	07-01-2019-Petitioner	Petitioner Exhibit List 36: Petitioner's Updated Exhibit List Petitioner Objection 37: Mylan Pharmaceuticals Inc. Objections to Evidence Submitted with Patent Owner Response Petitioner Exhibit 1042: Transcript of Telephone Conference on 6.19.19
6/25/2019	06-25-2019-Patent_Owner	Patent Owner Motion 34: Patent Owner's Contingent Motion to Amend Patent Owner Exhibit List 35: Patent Owner's Updated Exhibit List Patent Owner Exhibit 2120: Estelle Davis, et. al., An evaluation of prefilled insulin pens: a focus on the Next Generation FlexPen¿¿, Med. Devices: Evidence & Research, 41-50 (2010:3) Patent Owner Exhibit 2301: Disclosure Pursuant to 37 C.F.R. ¿¿ 42.11 Patent Owner Exhibit 2302: Declaration of Alexander Slocum, Ph.D. in Support of Sanofi¿¿¿s Motions to Amend Patent Owner Exhibit 2303: Table of Equivalent Disclosure in U.S. Applications 13/909,681 (¿¿¿486 Patent) and 15/156,616 (¿¿¿844 Patent) and Related Applications Patent Owner Exhibit 2304: U.S. Patent Application No. 15/156,616 and related documents extracted from the USPTO file history Patent Owner Exhibit 2305: U.S. Patent Application No. 14/946,203 and related documents extracted from the USPTO file history Patent Owner Exhibit 2306: U.S. Patent Application No. 14/635,573 and related documents extracted from the USPTO file history Patent Owner Exhibit 2307: U.S. Patent Application No. 13/919,251 and related documents extracted from the USPTO file history Patent Owner Exhibit 2308: U.S. Patent Application No. 13/040,198 and related documents extracted from the USPTO file history Patent Owner Exhibit 2309: U.S. Patent Application No. 11/483,546 and related documents extracted from the USPTO file history Patent Owner Exhibit 2310: U.S. Patent Application No. 10/790,225 and related documents extracted from the USPTO file history Patent Owner Exhibit 2311: U.S. Patent Application No. 13/909,681 and related documents extracted from the USPTO file history Patent Owner Exhibit 2312: U.S. Patent Application No. 12/944,544 and related documents extracted from the USPTO file history Patent Owner Exhibit 2313: Declaration of Chris Langley and Exhibit A, including an as-filed copy of GB 0304822.0 and related correspondence
6/25/2019	06-25-2019-Board	Board Order 33: ORDER - Conduct of the Proceeding Information and Guidance on Patent Owner¿¿¿s Proposed Motion to Amend 37 C.F.R. 42.5(a)
6/24/2019	06-24-2019-Patent_Owner	Patent Owner Response 32: Patent Owner's Response Patent Owner Exhibit 2100: Leinsing Deposition Exhibit 2100: Thomas van der Burg, Injection Force of SoloSTAR¿¿ Compared with Other Disposable Insulin Pen Devices at Constant Volume Flow Rates Patent Owner Exhibit 2101: Leinsing Deposition Exhibit 2101: Estelle Davis, et. al., An evaluation of prefilled insulin pens: a focuse on the Next Generation FlexPen¿¿ Patent Owner Exhibit 2102: Leinsing Deposition Exhibit 2102: Hand drawings Patent Owner Exhibit 2103: Leinsing Deposition Exhibit 2103: Annotations of Figures 6-15 of Burroughs Patent Owner Exhibit 2104: Leinsing Deposition Exhibit 2104: Annotations of Figures 5-8 of the 486 Patent Patent Owner Exhibit 2105: Leinsing Deposition Exhibit 2105: Hand drawings Patent Owner Exhibit 2106: Leinsing Deposition exhibit 2106: Annotations of Figures 11 and 12 of Giambattista Patent Owner Exhibit 2107: Declaration of Alexander Slocum, Ph.D. Patent Owner Exhibit 2108: Curriculum Vitae of Alexander Slocum, Ph.D. Patent Owner Exhibit 2109: Expert Report of Henry R. Grabowski, Ph.D. Patent Owner Exhibit 2110: Curriculum Vitae of Henry R. Grabowski, Ph.D. Patent Owner Exhibit 2111: Declaration of Dr. Robin S. Goland Patent Owner Exhibit 2112: Curriculum Vitae of Dr. Robin S. Goland Patent Owner Exhibit 2113: Bradley M. Wright et al., A Review Of Insulin Pen Devices And Use In The Elderly Diabetic Population Patent Owner Exhibit 2114: Teresa L. Pearson, A-Practical-Review-of-Insulin-Pen-Devices Patent Owner Exhibit 2115: Arthritis & Diabetes, What do diabetes and arthritis have in common? Patent Owner Exhibit 2116: Andreas Bode, Development of the SoloSTAR insulin pen device design verification and validation Patent Owner Exhibit 2117: Sanofi¿¿¿s Patented Pen animation Patent Owner Exhibit 2118: John Carter, Usability, Participant Acceptance, and Safety of a Prefilled Insulin Injection Device in a 3-Month Observational Survey in Everyday Clinical Practice in Australia Patent Owner Exhibit 2119: Sherwyn Schwartz, Correct Use of a New Reusable Insulin Injection Pen by Patients with Diabetes: A Design Validation Study Patent Owner Exhibit 2121: DBA Design Effectiveness Awards 2009 Patent Owner Exhibit 2122: SoloSTAR Disposable Pen Injector (The Grand Prix Oct. 22, 2009) Patent Owner Exhibit 2123: Arnd Friedrichs et al., Dose Accuracy and Injection Force of Different Insulin Glargine Pens Patent Owner Exhibit 2124: Stacey A. Seggelke et al., Effect of Glargine Insulin Delivery Method (Pen Device Versus Vial/Syringe) on Glycemic Control and Patient Preferences in Patients with Type 1 and Type 2 Diabetes Patent Owner Exhibit 2125: Julia Pfutzner et al., Evaluation of Dexterity in Insulin-Treated Patients with Type 1 and Type 2 Diabetes Mellitus Patent Owner Exhibit 2126: Jerome S. Fischer et al., United States Patient Preference and Usability for the New Disposable Insulin Device Solostar¿¿ versus Other Disposable Pens Patent Owner Exhibit 2127: U.S. Provisional Patent Application 60/073820 Patent Owner Exhibit 2128: Samita Garg et al., Insulin glargine and glulisine SoloSTAR pens for the treatment of diabetes Patent Owner Exhibit 2129: Nicolae Hancu et al., A Pan-European and Canadian Prospective Survey to Evaluate Patient Satisfaction with the SoloSTAR Insulin Injection Device in Type 1 and Type 2 Diabetes Patent Owner Exhibit 2130: Norbert Hermanns, Bernhard Kulzer & Thomas Haak, Dosing Accuracy with a Novel Pen Device (SoloSTAR) as Performed by Patients with Diabetes in a Clinical Setting Patent Owner Exhibit 2131: ISO 11608-1, Pen-injectors for medical use Patent Owner Exhibit 2132: Meike Krzywon et al., Study on the Dosing Accuracy of Commonly Used Disposable Insulin Pens Patent Owner Exhibit 2133: Lantus SoloSTAR Pen Guide Patent Owner Exhibit 2134: Arlan L. Rosenbloom, Limitation of Finger Joint Mobility in Diabetes Mellitus Patent Owner Exhibit 2135: Douglas Merritt et al., Dose Accuracy and Injection Force of Disposable Pens Delivering Pramlintide for the Treatment of Diabetes Patent Owner Exhibit 2136: Novo Nordisk Form 6-K (Feb. 9, 2009), Part One Patent Owner Exhibit 2136: Novo Nordisk Form 6-K (Feb. 9, 2009), Part Two Patent Owner Exhibit 2137: Novo Nordisk History, Part Two Patent Owner Exhibit 2137: Novo Nordisk History, Part One Patent Owner Exhibit 2138: W. Schady et al, Observations on Severe Ulnar Neuropathy in Diabetes Patent Owner Exhibit 2139: Alfred Penfornis & Kristian Horvat, Dose Accuracy Compariosn Between SoloSTAR and FlexPen at Three Different Dose Levels Patent Owner Exhibit 2140: John Shelmet et al., Preference and resource utilization in elderly patients: InnoLet versus vial/syringe Patent Owner Exhibit 2141: Prix Galien USA Announces 2009 Final Candidates Patent Owner Exhibit 2141: EXPUNGED Patent Owner Exhibit 2142: Prix Galien USA Announces 2009 Final Candidates Patent Owner Exhibit 2143: Thomas Haak et al., Comparison of Usability and Patient Preference for the New Disposable Insulin Device SoloStar Versus FlexPen, Lilly Disposable Pen, and a Prototype Pen: An Open-Label Study Patent Owner Exhibit 2144: Alastair Clarke & Geralyn Spollett, Dose accuracy and injection force dynamics of a novel disposable insulin pen Patent Owner Exhibit 2145: US Lantus SoloSTAR Launch Book Patent Owner Exhibit 2146: Lantus COMPASS Study Report, Part One Patent Owner Exhibit 2146: Lantus COMPASS Study Report, Part Two Patent Owner Exhibit 2147: Steenfeldt-Jensen 5th Embodiment Animation Patent Owner Exhibit 2148: Steenfeldt-Jensen 1st Embodiment Animation Patent Owner Exhibit 2149: Steenfeldt-Jensen 2nd Embodiment Animation Patent Owner Exhibit 2150: Steenfeldt-Jensen 5th Embodiment Thread and Slot Animation Patent Owner Exhibit 2151: Steenfeldt-Jensen 5th Embodiment vs. Proposed Modification Animation Patent Owner Exhibit 2152: Steenfeldt-Jensen 5th Embodiment vs. Proposed Modification Collar Friction Animation Patent Owner Exhibit 2153: International Patent Application WO999038554A1 Patent Owner Exhibit 2157: Declaration of Chris Langley Patent Owner Exhibit 2158: Geralyn Spollett, Insulin Devices, Addressing Barriers to Insulin Therapy With the Ideal Pen Patent Owner Exhibit 2159: Serpil Savas et al., The effects of the diabetes related soft tissue hand lesions and the reduced hand strength on functional disability of hand in type 2 diabetic patients Patent Owner Exhibit 2160: Jean-Louis Selam, Evolution of Diabetes Insulin Delivery Devices Patent Owner Exhibit 2161: SoloSTAR Principles of Operation Patent Owner Exhibit 2162: Sanofi Patent Drive Sleeve and Piston Rod Animation Patent Owner Exhibit 2163: Deposition of Karl R. Leinsing, dated June 3, 2019 for IPR2018-01675, -01676, -01678, -01680 Patent Owner Exhibit 2164: Deposition of Karl R. Leinsing, dated June 4, 2019 for IPR2018-01675, -01676, -01678, -01680 Patent Owner Exhibit 2165: Opinion and Order regarding Claim Construction, Sanofi-Aventis U.S. LLC v. Mylan, N.V., Civil Action No. 17-9105-SRC-SLW (D.N.J. May 9, 2019), Dkt. No. 319 Patent Owner Exhibit 2166: Memorandum and Order regarding Claim Construction, Sanofi-Aventis U.S. LLC v. Merck, No. 16-812-RGA (D. Del. Jan. 12, 2018), Dkt. No. 192 Patent Owner Exhibit 2167: Giambattista Animation (1) Patent Owner Exhibit 2168: Giambattista Animation (2) Patent Owner Exhibit 2169: U.S. Patent No. 4,648,872 Patent Owner Exhibit 2170: U.S. Patent No. 4,747,824 Patent Owner Exhibit 2171: U.S. Patent No. 6,248,093 Patent Owner Exhibit 2172: Karl R. Leinsing Declaration in Hologic, Inc. v. Minerva Surgical, Inc., No. 15-1031 (D. Del. Jan. 26, 2018), Dkt. No. 309 Patent Owner Exhibit 2173: Bruce A. Perkins, David Olaleye & Vera Bril, Carpal Tunnel Syndrome in Patients With Diabetic Polyneuropathy Patent Owner Exhibit 2174: Jefferson Becker et al., An evaluation of gender, obesity, age and diabetes mellitus as risk factors for carpal tunnel syndrome Patent Owner Exhibit 2175: A. Pfutzner et al., Prefilled insulin device with reduced injection force: patient perception and accuracy Patent Owner Exhibit 2176: Ercan Cetinus et al., Hand grip strength in patients with type 2 diabetes mellitus, Patent Owner Exhibit 2177: Ragnhild I. Cederlund et al., Hand disorders, hand function, and activities of daily living in elderly men with type 2 diabetes Patent Owner Exhibit 2178: Shubha Gundmi et al., Hand dysfunction in type 2 diabetes mellitus: Systematic review with meta-analysis Patent Owner Exhibit 2179: Joule J. Li et al., Muscle grip strength predicts incident type 2 diabetes: Population-based cohort study Patent Owner Exhibit 2180: Considering Insulin Pens for Routine Hospital Use Patent Owner Exhibit 2181: Trigger Finger Overview (Mayo Clinic) Patent Owner Exhibit 2182: Bone and joint problems associated with diabetes (Mayo Clinic) Patent Owner Exhibit 2183: Peripheral Neuropathy (Mayo Clinic) Patent Owner Exhibit 2184: Charles E. Buban, A pen that seeks to improve diabetes care Patent Owner Exhibit 2185: Sanofi-aventis¿¿¿ SoloSTAR(R) Insulin Pen for Lantus and Apidra Receives the Prestigious GOOD DESIGN Award Patent Owner Exhibit 2186: Select Injectable Insulin Drugs Approved by the FDA in the U.S. Patent Owner Exhibit 2187: U.S. Dollar Sales of Lantus SoloSTAR Patent Owner Exhibit 2188: U.S. New Prescriptions of Lantus SoloSTAR Patent Owner Exhibit 2189: U.S. Total Prescriptions of Lantus SoloSTAR Patent Owner Exhibit 2190: U.S. Share of Sales by Drugs in the Lantus Franchise Patent Owner Exhibit 2191: Formulary Placement of Long-Acting Insulin Pen Products: Commercial Plans Patent Owner Exhibit 2192: Formulary Placement of Long-Acting Insulin Pen Products: Medicare Plans Patent Owner Exhibit 2193: Formulary Placement of Long-Acting Insulin Pen Products: Medicaid Plans Patent Owner Exhibit 2194: Formulary Placement of Long-Acting Insulin Pen Products in Healthcare Exchanges Patent Owner Exhibit 2195: U.S. Share of Long-Acting Pens Among All Pens Patent Owner Exhibit 2196: U.S. Dollar Sales of Long-Acting Pens Patent Owner Exhibit 2197: U.S. New Prescriptions of Long-Acting Pens Patent Owner Exhibit 2198: U.S. Total Prescriptions of Long-Acting Pens Patent Owner Exhibit 2199: U.S. Share of Long-Acting Pen Products Patent Owner Exhibit 2200: Yuzu Sato et al., Clinical Aspects of physical exercise for diabetes/metabolic syndrome Patent Owner Exhibit 2201: 2007 Good Design Award from The Chicago Athenaeum: Museum of Architecture and Design Patent Owner Exhibit 2203: U.S. Total Marketing Expenditure of Long Acting Insulin Franchises Patent Owner Exhibit 2204: U.S. Total Marketing Expenditures of Long-Acting Insulin Pens Patent Owner Exhibit 2205: U.S. Marketing-to-Sales Ratios of Select Injectable Insulin Drugs Patent Owner Exhibit 2206: M¿¿ller First Embodiment Animation Patent Owner Exhibit 2207: M¿¿ller Second Embodiment Animation Patent Owner Exhibit 2208: Press Release, Lantus / Apdira SoloSTAR help to improve patient satisfaction Patent Owner Exhibit 2209: Henry Grabowski, John Vernon & Joseph A. DiMasi, Returns on Research and Development for 1990s New Drug Introductions Patent Owner Exhibit 2210: Julie M. Donohue, Marisa Cevasco & Meredith B. Rosenthal, A Decade of Direct-to-Consumer Advertising of Prescription Drugs Patent Owner Exhibit 2211: Collar Friction Model Demonstrator Animation Patent Owner Exhibit 2212: Excerpts from Ernest Rabinowicz, Friction And Wear of Materials, 2nd Edition Patent Owner Exhibit 2214: Excerpts from Alexander H. Slocum, Precision Machine Design Patent Owner Exhibit 2215: Collar Friction Model Demonstration 1 Patent Owner Exhibit 2216: Collar Friction Model Demonstration 2 Patent Owner Exhibit 2217: Collar Friction Model Demonstration 3 Patent Owner Exhibit 2218: SoloSTAR Dial Inject Video
6/11/2019	06-11-2019-Patent_Owner	Patent Owner Notice 31: PATENT OWNER'S UPDATED MANDATORY NOTICES PURSUANT TO 37 C.F.R. 42.8
6/3/2019	06-03-2019-Patent_Owner	Patent Owner Power of Attorney 30: Patent Owner's Power of Attorney
5/31/2019	05-31-2019-Patent_Owner	Patent Owner Notice of Deposition 29: Patent Owner's Updated Notice of Deposition of Karl R. Leinsing
5/23/2019	05-23-2019-Patent_Owner	Patent Owner Notice 27: PATENT OWNER¿¿¿S UPDATED MANDATORY NOTICES PURSUANT TO 37 C.F.R. 42.8 Patent Owner Notice of Deposition 28: PATENT OWNER¿¿¿S NOTICE OF DEPOSITION OF KARL R. LEINSING
5/9/2019	05-09-2019-Board	Board Order 26: PANEL CHANGE ORDER Conduct of the Proceedings 37 C.F.R. ¿¿ 42.5
4/16/2019	04-16-2019-Patent_Owner	Patent Owner Objection 25: Patent Owner's Objections to Documents Served with the Petition
4/16/2019	04-16-2019-Petitioner	Petitioner Objection 24: Mylan Pharmacetucials Inc. Objections to Evidence
4/3/2019	04-03-2019-Board	Board Institution Decision 22: Trial Instituted Document Board Order 23: Scheduling Order Board Exhibit 3001: Exhibit 3001
3/25/2019	03-25-2019-Petitioner	Petitioner Notice 20: Petitioner's Mandatory Change-Of-Information Notices Petitioner Power of Attorney 21: Petitioner's Power of Attorney
3/15/2019	03-15-2019-Board	Board Order 19: Order - 37 C.F.R. 42.10
2/28/2019	02-28-2019-Petitioner	Petitioner Motion 18: Mylan Pharmaceuticals Inc. Unopposed Motion for Pro Hac Vice Recognition Petitioner Exhibit 1040: Declaration of Elham F. Steiner ISO Unopposed Motion for Pro Hac Vice Recognition Petitioner Exhibit 1041: Elham F. Steiner, Attorney Biography
2/20/2019	02-20-2019-Board	Board Order 17: Expunging Duplicate Papers
2/15/2019	02-15-2019-Petitioner	Petitioner Exhibit List 16: Petitioners Updated Exhibit List Petitioner Exhibit 1039: Transcript of Call 02.13.2019
2/12/2019	02-12-2019-Patent_Owner	Patent Owner Reply 15: Patent Owner's Sur-Reply in Support of Patent Owner's Preliminary Response Patent Owner Exhibit 2010: Defendants¿¿¿ Opposition to Plaintiffs¿¿¿ Motion to Stay dated Nov.22, 2017, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 1:17-cv-00181-IMK (N.D. W. Va.), Dkt. No. 44 Patent Owner Exhibit 2011: Joint Proposed Discovery Plan dated Dec. 14, 2017, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRCCLW (D.N.J.) Patent Owner Exhibit 2012: Letter from A. Calmann to Judge Waldor dated Apr. 24, 2018,Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRC-CLW (D.N.J.), Dkt. No. 90 Patent Owner Exhibit 2013: Motion to Expedite Defendants¿¿¿ Motion Requesting an Expedited Scheduling Conference dated Nov. 22, 2017 , Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 1:17-cv-00181-IMK (N.D. W. Va.), Dkt. No. 46 Patent Owner Exhibit 2014: Initial Planning Meeting Report and Discovery Proposals dated Dec. 22, 2017, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 1:17-cv-00181-IMK (N.D. W. Va.), Dkt. No. 61 Patent Owner Exhibit 2015: Transcript of Motion / Scheduling Conference dated Jan. 3, 2018,Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 1:17-cv-00181-IMK (N.D. W. Va.), Dkt. No. 64 Patent Owner Exhibit 2016: Excerpts from Transcript, Conference Call dated Aug. 2, 2018,Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRC-CLW (D.N.J.) Patent Owner Exhibit 2017: Report of the Local Patent Rules Committee, Explanatory Notes for 2016 Amendments Patent Owner Exhibit 2018: Transcript, Conference Call for Case IPR2018-01675, -01676, -01678, -01680 (P.T.A.B. Feb. 5, 2019)
2/5/2019	02-05-2019-Board	Board Order 14: Order - 37 CFR 42.5
1/30/2019	01-30-2019-Petitioner	Petitioner Reply 13: Mylan Reply to Patent Owner's Preliminary Response Petitioner Exhibit 1038: Graph showing PTAB Days to Docketing for Review Proceedings filed between 2016-2018
1/29/2019	01-29-2019-Board	Board Order 12: Order - 37 C.F.R. Sect. 42.108(c)
1/22/2019	01-22-2019-Patent_Owner	Patent Owner Notice 10: Patent Owner's Updated Mandatory Notices Event: Preliminary Response Patent Owner Preliminary Response 11: Patent Owner's Preliminary Response Patent Owner Exhibit 2001: Press Release, ¿¿¿Mylan Enhances Partnership with Biocon through Strategic Collaboration for Insulin Products,¿¿¿ Feb. 13, 2013 (PR Newswire) Patent Owner Exhibit 2002: Press Release, ¿¿¿Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus¿¿ and Insulin Analog to Lantus¿¿,¿¿¿ Sept. 16, 2014 (PR Newswire) Patent Owner Exhibit 2003: Press Release, ¿¿¿Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association¿¿¿s 77th Scientific Sessions,¿¿¿ June 10, 2017 (PR Newswire) Patent Owner Exhibit 2004: First Amended and Supplemental Complaint for Patent Infringement, Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie v. Merck Sharp & Dohme Corp., C.A. No. 1:16-cv-00812-RGA (D. Del) Patent Owner Exhibit 2005: Stipulation and Proposed Order, Sanofi-Aventis U.S. LLC v. Mylan, N.V., Civil Action No. 17-9105-SRC-SLW (D.N.J. Feb 5, 2018) Patent Owner Exhibit 2006: Complaint for Patent Infringement, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRC-CLW (D.N.J. Oct. 24, 2017) Patent Owner Exhibit 2007: Excerpts from Defendants¿¿¿ Invalidity Contentions, dated Jan. 25, 2018, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRC-CLW (D.N.J.) Patent Owner Exhibit 2008: Excerpts from Mylan GMBH¿¿¿s Amended Invalidity Contentions, dated April 25, 2018, Sanofi-Aventis U.S. LLC et al. v. Mylan N.V. et al., Case No. 2:17-cv-09105-SRC-CLW (D.N.J.) Patent Owner Exhibit 2009: EXPUNGED
10/30/2018	10-30-2018-Petitioner	Petitioner Notice 9: Updated Mandatory Notices
10/19/2018	10-19-2018-Board	Board Notice of Filing Date Accorded to Petition 8: Notice of Accord Filing Date
10/12/2018	10-12-2018-Petitioner	Petitioner Notice 7: Petitioner's Mandatory Change-of-Information Notices
9/27/2018	09-27-2018-Patent_Owner	Patent Owner Power of Attorney 5: Power of Attorney Patent Owner Mandatory Notice 6: Patent Owner's Mandatory Notices Pursuant To 37 C.F.R. 42.8
9/13/2018	09-13-2018-Petitioner	Petitioner Notice 4: Petitioner¿¿¿s Mandatory Change-of-Information Notices Under 37 C.F.R. ¿¿42.8(A)(3)
9/10/2018	09-10-2018-Petitioner	Petitioner Power of Attorney 1: Petitioner Mylan Pharmaceuticals Inc. Power of Attorney Event: Petition Petitioner Petition 2: Petition for IPR of USP 9,526,844 Event: Petition Petitioner Petition 3: EXPUNGED Petitioner Exhibit 1001: USP 8,679,069 Petitioner Exhibit 1002: USP 8,603,044 Petitioner Exhibit 1003: USP 8,992,486 Petitioner Exhibit 1004: USP 9,526,844 Petitioner Exhibit 1005: USP 9,604,008 Petitioner Exhibit 1006: File History for U.S. Patent 8,679,069 Petitioner Exhibit 1007: File History for U.S. Patent 8,603,044 Petitioner Exhibit 1008: File History for U.S. Patent 8,992,486 Petitioner Exhibit 1009: File History for U.S. Patent 9,526,844 Petitioner Exhibit 1010: File History for U.S. Patent. 9,604,008 Petitioner Exhibit 1011: Expert Declaration of Karl Leinsing MSME, PE in Support of Petition for Inter Partes Review of U.S. Patent Nos. 8,679,069; 8,603,044; 8,992,486; 9,526,844 and 9,604,008 Petitioner Exhibit 1012: Curriculum Vitae of Karl Leinsing MSME,PE Petitioner Exhibit 1013: U.S. Patent 6,221,046 - A. Burroughs et al., ¿¿¿Recyclable Medication Dispensing Device¿¿¿ (issued Apr. 24, 2001) Petitioner Exhibit 1014: U.S. Patent 6,235,004 ¿¿¿ S. Steenfeldt-Jensen & S. Hansen, ¿¿¿Injection Syringe¿¿¿ (issued May 22, 2001) Petitioner Exhibit 1015: U.S. Patent Application US 2002/0053578 A1 ¿¿¿ C.S. M¿¿ller, ¿¿¿Injection Device¿¿¿ (pub¿¿¿d May 2, 2002) Petitioner Exhibit 1016: U.S. Patent 6,932,794 B2 ¿¿¿ L. Giambattista & A. Bendek, ¿¿¿Medication Delivery Pen¿¿¿ (issued Aug. 23, 2005) Petitioner Exhibit 1017: U.S. Patent 6,582,404 B1 ¿¿¿ P.C. Klitgaard et al., ¿¿¿Dose Setting Limiter¿¿¿ (issued June 24, 2003) Petitioner Exhibit 1018: File History for U.S. Patent 6,582,404 Petitioner Exhibit 1019: Plaintiffs¿¿¿ Preliminary Claim Constructions and Preliminary Identification of Supporting Intrinsic and Extrinsic Evidence, Sanofi-Aventis U.S. LLC v. Mylan GmbH, No. 2:17-cv-09105 (D.N.J.) (filed Sep. 5 2018) Petitioner Exhibit 1020: U.S. Patent 4,865,591 ¿¿¿ B. Sams, ¿¿¿Measured Dose Dispensing Device¿¿¿ (issued Sep. 12, 1989) Petitioner Exhibit 1021: U.S. Patent 6,248,095 B1 ¿¿¿ L. Giambattista et al., ¿¿¿Low-cost Medication Delivery Pen¿¿¿ (issued June 19, 2001) Petitioner Exhibit 1022: U.S. Patent 6,921,995 B1 ¿¿¿ A.A. Bendek et al., ¿¿¿Medication Delivery Pen Having An Improved Clutch Assembly¿¿¿ (issued July 13, 1999) Petitioner Exhibit 1023: U.S. Patent 5,226,895 ¿¿¿ D.C. Harris, ¿¿¿Multiple Dose Injection Pen¿¿¿ (issued July 13, 1993) Petitioner Exhibit 1024: U.S. Patent 5,851,079 ¿¿¿ R.L. Horstman et al., ¿¿¿Simplified Unidirectional Twist-Up Dispensing Device With Incremental Dosing¿¿¿ (issued Dec. 22, 1998) Petitioner Exhibit 1025: Application as filed: U.S. Patent App. 14/946,203 ¿¿¿ R.F. Veasey, ¿¿¿Relating to a Pen-Type Injector¿¿¿ (filed Nov. 19, 2015) Petitioner Exhibit 1026: GB 0304822.0 ¿¿¿ ¿¿¿Improvements in and relating to a pen-type injector¿¿¿ (filed Mar. 3, 2003) (¿¿¿844 Priority Doc.) Petitioner Exhibit 1027: WO 99/38554 ¿¿¿ S.Steenfeldt-Jensen & S.Hansen, ¿¿¿An Injection Syringe¿¿¿ (pub¿¿¿d Aug. 5, 1999) (Steenfeldt-Jensen PCT) Petitioner Exhibit 1028: Mylan GmbH and Biocon¿¿¿s Preliminary Claim Constructions and Supporting Evidence Pursuant to L. Pat. R. 4.2, Sanofi-Aventis U.S., LLC v. Mylan N.V., C.A. No. 17-cv-09105 (filed Sep. 5, 2018) Petitioner Exhibit 1029: Memorandum Opinion, Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp., No. 16-cv-812 (filed Jan. 12, 2018) Petitioner Exhibit 1030: Memorandum Opinion, Sanofi -Aventis U.S. LLC v. Eli Lily and Co., No. 14-cv-113 (filed Jan. 20, 2015) Petitioner Exhibit 1031: N. Sclater & N.P. Chironis, Mechanisms & Mechanical Devices Sourcebook 191-95, ¿¿¿Twenty Screw Devices¿¿¿ (3d ed., July 2, 2001) Petitioner Exhibit 1032: EP 0 608 343 B1 ¿¿¿ L. Petersen & N.-A. Hansen, ¿¿¿Large Dose Pen¿¿¿ (pub¿¿¿d Oct. 18, 1991) Petitioner Exhibit 1033: A.G. Erdman &G.N. Sandor, ¿¿¿ Mechanical Advantage¿¿¿, ¿¿3.7 in 1 Mechanism Design: Analysis and Synthesis (1984) Petitioner Exhibit 1034: WO 01/83008 ¿¿¿ S. Hansen & T.D. Miller., ¿¿¿An Injection Device, A Preassembled Dose Setting And Injection Mechanism For An Injection Device, And A Method Of Assembling An Injection Device¿¿¿ (pub¿¿¿d Nov. 8, 2001) Petitioner Exhibit 1035: K.J. Lipska et al., Association of Initiation of Basal Insulin Analogs vs Neutral Protamine Hagedorn Insulin With Hypoglycemia-Related Emergency Department Visits ... 320 J. Am. Med. Ass¿¿¿n 53-62 (2018).

Supplemental Search

Search for PTAB Motions

PTAB Analytics

TTAB Analytics

Basic Search

Filters

Party Search

Advanced

Selected Courts

Recently Selected Courts

Find PTAB Decisions

PTAB Analytics

Special PTAB Alerts

Orange Book

Directly Search Federal Courts

Search Trademark ...

Search millions of cases and get court filings, fast docket alerts, and case analytics.

Request a Demo or create your account.

Lawyer? Your firm may have a group account, ask us and we'll let you know.

Patent Owner

Petitioners

Keyboard shortcuts

Filtering / Searching the Docket

Interactive Timeline

Mylan Pharmaceuticals Inc v. Sanofi-Aventis Deutschland GmbH

IPR2018-01680 | Patent Trial and Appeal Board

Interested in this case?

Event:

Event:

Event:

Event:

Event:

Alert Sharing

STEP 2 of 2

Choose your membership type

Flat-Fee

Pay-As-You-Go Monthly

Add your payment information

Login or Join

Enter your corporate Email

Thousands of your peers are saving time and gaining a competitive advantage with Docket Alarm.

Join Docket Alarm to perform smarter legal research.

Download this document and millions of others instantly with a Docket Alarm membership.

Join Docket Alarm and start performing smarter legal research.

Start tracking this docket instantly with a Docket Alarm membership.

Join thousands of your peers and start performing smarter legal research.

STEP 1 of 2

Millions of Documents | 15 Seconds to Signup

Hi !

Welcome to Docket Alarm

Welcome to Docket Alarm!

Explore Litigation Insights andManage Your Cases

Reset Password

What is PACER?

Why do I need it?

What will I be charged?

Do other courts have fees?

Basic Free Access

Welcome

Thank you

Check Firm Account

Explore Litigation Insights and
Manage Your Cases